Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia

References

• Gentzler RD, Altman JK, Platanias LC. An overview of the mTOR pathway as a target in cancer therapy. Expert Opin Ther Targets 2012; 16:481–9; PMID:22494490; http://dx.doi.org/10.1517/14728222.2012.677439
   PubMed Web of Science ®Google Scholar
• Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27:5497–510; PMID:18794884; http://dx.doi.org/10.1038/onc.2008.245
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mosca A. Targeting PI3K/AKT/mTOR Signaling in Cancer. Front Oncol 2014; 4:64; PMID:24782981; http://dx.doi.org/10.3389/fonc.2014.00064
   PubMedGoogle Scholar
• Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010; 15:428–35; PMID:20332142; http://dx.doi.org/10.1634/theoncologist.2009-0178
   PubMed Web of Science ®Google Scholar
• Lebwohl D, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T, Posluszny J, Saletan S, Berg W. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci 2013; 1291:14–32; PMID:23659703; http://dx.doi.org/10.1111/nyas.12122
   PubMed Web of Science ®Google Scholar
• Markham A. Idelalisib: first global approval. Drugs 2014; 74:1701–7; PMID:25187123; http://dx.doi.org/10.1007/s40265-014-0285-6
   PubMed Web of Science ®Google Scholar
• Altman JK, Platanias LC. Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. Int J Hematol Oncol 2013; 2:10.2217/ijh.13.23; PMID:24319589; http://dx.doi.org/10.2217/ijh.13.23
   PubMedGoogle Scholar
• Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 2009; 18:1333–49; PMID:19678801; http://dx.doi.org/10.1517/14728220903136775
   PubMed Web of Science ®Google Scholar
• Min YH, Eom JI, Cheong JW, Maeng HO, Kim JY, Jeung HK, Lee ST, Lee MH, Hahn JS, Ko YW. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003; 17:995–7; PMID:12750723; http://dx.doi.org/10.1038/sj.leu.2402874
   PubMed Web of Science ®Google Scholar
• Bertacchini J, Guida M, Accordi B, Mediani L, Martelli AM, Barozzi P, Petricoin E, 3rd, Liotta L, Milani G, Giordan M, et al. Feedbacks and adaptive capabilities of the PI3K/AKT/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. Leukemia 2014; 28:2197–205; PMID:24699302; http://dx.doi.org/10.1038/leu.2014.123
   PubMed Web of Science ®Google Scholar
• Zeng Z, Shi YX, Tsao T, Qiu Y, Kornblau SM, Baggerly KA, Liu W, Jessen K, Liu Y, Kantarjian H, et al. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood 2012; 120:2679–89; PMID:22826565; http://dx.doi.org/10.1182/blood-2011-11-393934
   PubMed Web of Science ®Google Scholar
• Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102:972–80; PMID:12702506; http://dx.doi.org/10.1182/blood-2002-11-3429
   PubMed Web of Science ®Google Scholar
• Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105:2527–34; PMID:15550488; http://dx.doi.org/10.1182/blood-2004-06-2494
   PubMed Web of Science ®Google Scholar
• Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 2007; 14:2009–23; PMID:17691943; http://dx.doi.org/10.2174/092986707781368423
   PubMed Web of Science ®Google Scholar
• Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 2012; 119:34–43; PMID:22086414; http://dx.doi.org/10.1182/blood-2011-04-347872
   PubMed Web of Science ®Google Scholar
• Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets 2011; 11:56–71; PMID:21062243; http://dx.doi.org/10.2174/156800911793743655
   PubMed Web of Science ®Google Scholar
• Zeijlemaker W, Gratama JW, Schuurhuis GJ. Tumor heterogeneity makes AML a “moving target” for detection of residual disease. Cytometry B Clin Cytom 2014; 86:3–14; PMID:24151248; http://dx.doi.org/10.1002/cyto.b.21134
   PubMed Web of Science ®Google Scholar
• Shah A, Andersson TM, Rachet B, Bjorkholm M, Lambert PC. Survival and cure of acute myeloid leukaemia in England, 1971–2006: a population-based study. Br J Haematol 2013; 162:509–16; PMID:23786647; http://dx.doi.org/10.1111/bjh.12425
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116:354–65; PMID:20385793; http://dx.doi.org/10.1182/blood-2009-11-254441
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012; 366:1079–89; PMID:22417203; http://dx.doi.org/10.1056/NEJMoa1112304
   PubMed Web of Science ®Google Scholar
• Sujobert P, Bardet V, Cornillet-Lefebvre P, Hayflick JS, Prie N, Verdier F, Vanhaesebroeck B, Muller O, Pesce F, Ifrah N, et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005; 106:1063–6; PMID:15840695; http://dx.doi.org/10.1182/blood-2004-08-3225
   PubMed Web of Science ®Google Scholar
• Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Vanhaesebroeck B, Khwaja A. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006; 25:6648–59; PMID:16702948; http://dx.doi.org/10.1038/sj.onc.1209670
   PubMed Web of Science ®Google Scholar
• Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011; 2:510–7; PMID:21680954
   PubMed Web of Science ®Google Scholar
• Sanja P, Ivo U, Boris L, Damir N, Josip B, Renata Z, Suncica R, Koraljka GK, Sanja D, Drago B. Prognostic significance of constitutive PI3K/Akt and MAPK phosphorylation in acute myeloid leukemia. Leuk Lymphoma 2014; published on line December 29 2014, http://dx.doi.org/10.3109/10428194.2014.990012
   Google Scholar
• Jucker M, Sudel K, Horn S, Sickel M, Wegner W, Fiedler W, Feldman RA. Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin's lymphoma-derived cell line (CO). Leukemia 2002; 16:894–901; PMID:11986952; http://dx.doi.org/10.1038/sj.leu.2402484
   PubMed Web of Science ®Google Scholar
• Muller CI, Miller CW, Hofmann WK, Gross ME, Walsh CS, Kawamata N, Luong QT, Koeffler HP. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 2007; 31:27–32; PMID:16764926; http://dx.doi.org/10.1016/j.leukres.2006.04.011
   PubMed Web of Science ®Google Scholar
• Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood 2012; 120:3397–406; PMID:22898602; http://dx.doi.org/10.1182/blood-2012-05-378596
   PubMed Web of Science ®Google Scholar
• Johnson DB, Smalley KS, Sosman JA. Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res 2014; 20:4186–92; PMID:24895460; http://dx.doi.org/10.1158/1078-0432.CCR-13-3270
   PubMed Web of Science ®Google Scholar
• Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11:761–74; PMID:21993244; http://dx.doi.org/10.1038/nrc3106
   PubMed Web of Science ®Google Scholar
• Lonetti A, Antunes IL, Chiarini F, Orsini E, Buontempo F, Ricci F, Tazzari PL, Pagliaro P, Melchionda F, Pession A, et al. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia 2014; 28:1196–206; PMID:24310736; http://dx.doi.org/10.1038/leu.2013.369
   PubMed Web of Science ®Google Scholar
• Nguyen LX, Sesay A, Mitchell BS. Effect of CAL-101, a PI3Kdelta inhibitor, on ribosomal rna synthesis and cell proliferation in acute myeloid leukemia cells. Blood Cancer J 2014; 4:e228; PMID:25014775; http://dx.doi.org/10.1038/bcj.2014.49
   PubMedGoogle Scholar
• Gritsman K, Yuzugullu H, Von T, Yan H, Clayton L, Fritsch C, Maira SM, Hollingworth G, Choi C, Khandan T, et al. Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha. J Clin Invest 2014; 124:1794–809; PMID:24569456; http://dx.doi.org/10.1172/JCI69927
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098–101; PMID:15718470; http://dx.doi.org/10.1126/science.1106148
   PubMed Web of Science ®Google Scholar
• Sandhofer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiss V, Carlet M, Walter G, Hinrichsen T, Wachter O, et al. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. Leukemia 2014; Oct 17; [Epub ahead of print]; PMID:25322685, http://dx.doi.org/10.1038/leu.2014.305
   PubMedGoogle Scholar
• Castellano E, Downward J. Role of RAS in the regulation of PI 3-kinase. Curr Top Microbiol Immunol 2010; 346:143–69; PMID:20563706
   PubMed Web of Science ®Google Scholar
• Wunderle L, Badura S, Lang F, Wolf A, Schleyer E, Serve H, Goekbuget N, Pfeifer H, Bug G, Ottmann OG. Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study. Blood 2013; 122: abstract 2675
   Google Scholar
• Chen J, Shao R, Li L, Xu ZP, Gu W. Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways. Int J Nanomedicine 2014; 9:3403–11; PMID:25075187
   PubMed Web of Science ®Google Scholar
• Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M, Ottmann OG. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia. PLoS One 2013; 8:e80070; PMID:24244612; http://dx.doi.org/10.1371/journal.pone.0080070
   PubMed Web of Science ®Google Scholar
• Jabbour E, Ottmann OG, Deininger M, Hochhaus A. Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica 2014; 99:7–18; PMID:24425689; http://dx.doi.org/10.3324/haematol.2013.087171
   PubMed Web of Science ®Google Scholar
• Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Dohner H, Dohner K, Schittenhelm MM. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer 2013; 12:46; PMID:23705826; http://dx.doi.org/10.1186/1476-4598-12-46
   PubMed Web of Science ®Google Scholar
• Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997; 7:261–9; PMID:9094314; http://dx.doi.org/10.1016/S0960-9822(06)00122-9
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000; 346:561–76; PMID:10698680; http://dx.doi.org/10.1042/0264-6021:3460561
   PubMed Web of Science ®Google Scholar
• Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91:231–41; PMID:9346240; http://dx.doi.org/10.1016/S0092-8674(00)80405-5
   PubMed Web of Science ®Google Scholar
• Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999; 401:86–90; PMID:10485711; http://dx.doi.org/10.1038/43474
   PubMed Web of Science ®Google Scholar
• Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12:3499–511; PMID:9832503; http://dx.doi.org/10.1101/gad.12.22.3499
   PubMed Web of Science ®Google Scholar
• Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002; 4:648–57; PMID:12172553; http://dx.doi.org/10.1038/ncb839
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857–68; PMID:10102273; http://dx.doi.org/10.1016/S0092-8674(00)80595-4
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci 2013; 126:1713–19; PMID:23641065; http://dx.doi.org/10.1242/jcs.125773
   PubMed Web of Science ®Google Scholar
• Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwable J, Buerger H, Muller-Tidow C, Choudhary C, McMahon M, et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 2005; 65:9643–50; PMID:16266983; http://dx.doi.org/10.1158/0008-5472.CAN-05-0422
   PubMed Web of Science ®Google Scholar
• Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005; 19:586–94; PMID:15703783
   PubMed Web of Science ®Google Scholar
• Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C, Recher C. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 2009; 23:1029–38; PMID:19158829; http://dx.doi.org/10.1038/leu.2008.395
   PubMed Web of Science ®Google Scholar
• Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, et al. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res 2013; 37:1461–67; PMID:23993427; http://dx.doi.org/10.1016/j.leukres.2013.07.034
   PubMed Web of Science ®Google Scholar
• Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, et al. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008; 22:147–60; PMID:17928881; http://dx.doi.org/10.1038/sj.leu.2404980
   PubMed Web of Science ®Google Scholar
• Krawczyk J, Keane N, Swords R, O'Dwyer M, Freeman CL, Giles FJ. Perifosine–a new option in treatment of acute myeloid leukemia? Expert Opin Investig Drugs 2013; 22:1315–27; PMID:23931614; http://dx.doi.org/10.1517/13543784.2013.826648
   PubMed Web of Science ®Google Scholar
• Richardson PG, Nagler A, Ben-Yehuda D, Badros A, Hari P, Hajek R, Spicka I, Kaya H, Le Blanc R, Yoon S-S, et al. Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib. Blood 2013; 122: abstract 3189; http://dx.doi.org/10.1182/blood-2013-01-481325
   Web of Science ®Google Scholar
• Figg WD, Monga M, Headlee D, Shah A, Chau CH, Peer C, Messman R, Elsayed YA, Murgo AJ, Melillo G, et al. A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. Cancer Chemother Pharmacol 2014; 74:955–67; PMID:25183650; http://dx.doi.org/10.1007/s00280-014-2569-7
   PubMed Web of Science ®Google Scholar
• Gojo I, Perl A, Luger S, Baer MR, Norsworthy KJ, Bauer KS, Tidwell M, Fleckinger S, Carroll M, Sausville EA. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Invest New Drugs 2013; 31:1217–27; PMID:23443507; http://dx.doi.org/10.1007/s10637-013-9937-8
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9:1956–67; PMID:20571069; http://dx.doi.org/10.1158/1535-7163.MCT-09-1012
   PubMed Web of Science ®Google Scholar
• Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008; 68:2366–74; PMID:18381444; http://dx.doi.org/10.1158/0008-5472.CAN-07-5783
   PubMed Web of Science ®Google Scholar
• Konopleva MY, Walter RB, Faderl SH, Jabbour EJ, Zeng Z, Borthakur G, Huang X, Kadia TM, Ruvolo PP, Feliu JB, et al. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res 2014; 20:2226–35; PMID:24583795; http://dx.doi.org/10.1158/1078-0432.CCR-13-1978
   PubMed Web of Science ®Google Scholar
• Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 2010; 5:e14124; PMID:21124782; http://dx.doi.org/10.1371/journal.pone.0014124
   PubMed Web of Science ®Google Scholar
• Floc'h N, Kinkade CW, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A, Cardiff RD, Califano A, Shen MM, Abate-Shen C. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res 2012; 72:4483–93; PMID:22815528; http://dx.doi.org/10.1158/0008-5472.CAN-12-0283
   PubMed Web of Science ®Google Scholar
• Sun D, Sawada A, Nakashima M, Kobayashi T, Ogawa O, Matsui Y. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway. Urol Oncol 2014; S1078-1439(14)00363–9 published on line December 9 2014, http://dx.doi.org/10.1016/j.urolonc.2014.10.018
   Google Scholar
• Levy DS, Kahana JA, Kumar R. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood 2009; 113:1723–29; PMID:19064730; http://dx.doi.org/10.1182/blood-2008-02-137737
   PubMed Web of Science ®Google Scholar
• Lucero-Acuna A, Jeffery JJ, Abril ER, Nagle RB, Guzman R, Pagel MD, Meuillet EJ. Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer. Int J Nanomedicine 2014; 9:5653–65; PMID:25516710
   PubMed Web of Science ®Google Scholar
• Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010; 11:9–22; PMID:20027184; http://dx.doi.org/10.1038/nrm2822
   PubMed Web of Science ®Google Scholar
• Flynn P, Wongdagger M, Zavar M, Dean NM, Stokoe D. Inhibition of PDK-1 activity causes a reduction in cell proliferation and survival. Curr Biol 2000; 10:1439–42; PMID:11102805; http://dx.doi.org/10.1016/S0960-9822(00)00801-0
   PubMed Web of Science ®Google Scholar
• Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009; 16:21–32; PMID:19573809; http://dx.doi.org/10.1016/j.ccr.2009.04.012
   PubMed Web of Science ®Google Scholar
• Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, Zhu D, Biroc SL, Alicke B, Bryant J, Yuan S, et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 2005; 280:19867–74; PMID:15772071; http://dx.doi.org/10.1074/jbc.M501367200
   PubMed Web of Science ®Google Scholar
• Peifer C, Alessi DR. Small-molecule inhibitors of PDK1. ChemMedChem 2008; 3:1810–38; PMID:18972468; http://dx.doi.org/10.1002/cmdc.200800195
   PubMed Web of Science ®Google Scholar
• Najafov A, Sommer EM, Axten JM, Deyoung MP, Alessi DR. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J 2011; 433:357–69; PMID:21087210; http://dx.doi.org/10.1042/BJ20101732
   PubMed Web of Science ®Google Scholar
• Pearn L, Fisher J, Burnett AK, Darley RL. The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood 2007; 109:4461–69; PMID:17255356; http://dx.doi.org/10.1182/blood-2006-09-047217
   PubMed Web of Science ®Google Scholar
• Aihara H, Asaoka Y, Yoshida K, Nishizuka Y. Sustained activation of protein kinase C is essential to HL-60 cell differentiation to macrophage. Proc Natl Acad Sci U S A 1991; 88:11062–66; PMID:1763021; http://dx.doi.org/10.1073/pnas.88.24.11062
   PubMed Web of Science ®Google Scholar
• Zabkiewicz J, Pearn L, Hills RK, Morgan RG, Tonks A, Burnett AK, Darley RL. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 2014; 99:858–64; PMID:24334295; http://dx.doi.org/10.3324/haematol.2013.096487
   PubMed Web of Science ®Google Scholar
• Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408:297–315; PMID:17850214; http://dx.doi.org/10.1042/BJ20070797
   PubMed Web of Science ®Google Scholar
• Clark K, Plater L, Peggie M, Cohen P. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J Biol Chem 2009; 284:14136–46; PMID:19307177; http://dx.doi.org/10.1074/jbc.M109.000414
   PubMed Web of Science ®Google Scholar
• Medina JR, Becker CJ, Blackledge CW, Duquenne C, Feng Y, Grant SW, Heerding D, Li WH, Miller WH, Romeril SP, et al. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors. J Med Chem 2011; 54:1871–95; PMID:21341675; http://dx.doi.org/10.1021/jm101527u
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274–93; PMID:22500797; http://dx.doi.org/10.1016/j.cell.2012.03.017
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21–35; PMID:21157483; http://dx.doi.org/10.1038/nrm3025
   PubMed Web of Science ®Google Scholar
• Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP, Kasuga M, Nishimoto I, Avruch J. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 1997; 272:26457–63; PMID:9334222; http://dx.doi.org/10.1074/jbc.272.42.26457
   PubMed Web of Science ®Google Scholar
• Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12:5165–73; PMID:16951235; http://dx.doi.org/10.1158/1078-0432.CCR-06-0764
   PubMed Web of Science ®Google Scholar
• Bohm A, Aichberger KJ, Mayerhofer M, Herrmann H, Florian S, Krauth MT, Derdak S, Samorapoompichit P, Sonneck K, Vales A, et al. Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells. Eur J Clin Invest 2009; 39:395–405; PMID:19320940; http://dx.doi.org/10.1111/j.1365-2362.2009.02101.x
   PubMed Web of Science ®Google Scholar
• Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009; 15:6732–9; PMID:19843663; http://dx.doi.org/10.1158/1078-0432.CCR-09-0842
   PubMed Web of Science ®Google Scholar
• Janus A, Linke A, Cebula B, Robak T, Smolewski P. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine. Anticancer Drugs 2009; 20:693–701; PMID:19584709; http://dx.doi.org/10.1097/CAD.0b013e32832e89b4
   PubMed Web of Science ®Google Scholar
• Callera F, Lopes CO, Rosa ES, Mulin CC. Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome. Leuk Res 2008; 32:1633–4; PMID:18405970; http://dx.doi.org/10.1016/j.leukres.2008.02.004
   PubMed Web of Science ®Google Scholar
• Boehm A, Mayerhofer M, Herndlhofer S, Knoebl P, Sillaber C, Sperr WR, Jaeger U, Valent P. Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML. Eur J Intern Med 2009; 20:775–8; PMID:19892307; http://dx.doi.org/10.1016/j.ejim.2009.09.007
   PubMed Web of Science ®Google Scholar
• Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, et al. A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res 2013; 37:1622–7; PMID:24138944; http://dx.doi.org/10.1016/j.leukres.2013.09.002
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008; 14:2756–62; PMID:18451242; http://dx.doi.org/10.1158/1078-0432.CCR-07-1372
   PubMed Web of Science ®Google Scholar
• Park S, Chapuis N, Saint Marcoux F, Recher C, Prebet T, Chevallier P, Cahn JY, Leguay T, Bories P, Witz F, et al. A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia 2013; 27:1479–86; PMID:23321953; http://dx.doi.org/10.1038/leu.2013.17
   PubMed Web of Science ®Google Scholar
• Amadori S, Stasi R, Martelli AM, Venditti A, Meloni G, Pane F, Martinelli G, Lunghi M, Pagano L, Cilloni D, et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol 2012; 156:205–12; PMID:22082314; http://dx.doi.org/10.1111/j.1365-2141.2011.08940.x
   PubMed Web of Science ®Google Scholar
• Altman JK, Sassano A, Kaur S, Glaser H, Kroczynska B, Redig AJ, Russo S, Barr S, Platanias LC. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011; 17:4378–88; PMID:21415215; http://dx.doi.org/10.1158/1078-0432.CCR-10-2285
   PubMed Web of Science ®Google Scholar
• Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 2012; 26:1195–202; PMID:22143671; http://dx.doi.org/10.1038/leu.2011.339
   PubMed Web of Science ®Google Scholar
• Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111:379–82; PMID:17878402; http://dx.doi.org/10.1182/blood-2007-03-080796
   PubMed Web of Science ®Google Scholar
• Zeng Z, Wang R-Y, Shi Y, Qiu Y, Mak DH, Coombes K, Yoo SY, Jessen K, Liu Y, Rommel C, et al. MLN0128, a second-generation mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML. Blood 2014; 124: abstract 3613; PMID:25261197; http://dx.doi.org/10.1182/blood-2014-01-551457
   PubMed Web of Science ®Google Scholar
• Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res 2014; 20:490–8; PMID:24178622; http://dx.doi.org/10.1158/1078-0432.CCR-13-1311
   PubMed Web of Science ®Google Scholar
• Meja K, Stengel C, Sellar R, Huszar D, Davies BR, Gale RE, Linch DC, Khwaja A. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br J Haematol 2014; 167:69–79; PMID:24975213; http://dx.doi.org/10.1111/bjh.13013
   PubMed Web of Science ®Google Scholar
• Teo T, Yu M, Yang Y, Gillam T, Lam F, Sykes MJ, Wang S. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis chronic myeloid leukemia cells. Cancer Lett 2014; 357:612–23; PMID:25527453; http://dx.doi.org/10.1016/j.canlet.2014.12.029
   PubMed Web of Science ®Google Scholar
• Joshi S, Platanias LC. Mnk kinase pathway: cellular functions and biological outcomes. World J Biol Chem 2014; 5:321–33; PMID:25225600; http://dx.doi.org/10.4331/wjbc.v5.i3.321
   PubMedGoogle Scholar
• Altman JK, Szilard A, Goussetis DJ, Sassano A, Colamonici M, Gounaris E, Frankfurt O, Giles FJ, Eklund EA, Beauchamp EM, et al. Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin Cancer Res 2014; 20:2400–9; PMID:24610825; http://dx.doi.org/10.1158/1078-0432.CCR-13-3218
   PubMed Web of Science ®Google Scholar
• Wong PM, Puente C, Ganley IG, Jiang X. The ULK1 complex: sensing nutrient signals for autophagy activation. Autophagy 2013; 9:124–37; PMID:23295650; http://dx.doi.org/10.4161/auto.23323
   PubMed Web of Science ®Google Scholar
• Han W, Sun J, Feng L, Wang K, Li D, Pan Q, Chen Y, Jin W, Wang X, Pan H, et al. Autophagy inhibition enhances daunorubicin-induced apoptosis in K562 cells. PLoS One 2011; 6:e28491; PMID:22164300; http://dx.doi.org/10.1371/journal.pone.0028491
   PubMed Web of Science ®Google Scholar
• Bosnjak M, Ristic B, Arsikin K, Mircic A, Suzin-Zivkovic V, Perovic V, Bogdanovic A, Paunovic V, Markovic I, Bumbasirevic V, et al. Inhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic death. PLoS One 2014; 9:e94374; PMID:24714637; http://dx.doi.org/10.1371/journal.pone.0094374
   PubMed Web of Science ®Google Scholar
• Amaravadi RK, Winkler JD. Lys05: a new lysosomal autophagy inhibitor. Autophagy 2012; 8:1383–84; PMID:22878685; http://dx.doi.org/10.4161/auto.20958
   PubMed Web of Science ®Google Scholar
• Kaneko M, Nozawa H, Hiyoshi M, Tada N, Murono K, Nirei T, Emoto S, Kishikawa J, Iida Y, Sunami E, et al. Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells. J Cancer Res Clin Oncol 2014; 140:769–81; PMID:24619662; http://dx.doi.org/10.1007/s00432-014-1628-0
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE, Mita AC, Curiel TJ, Espitia CM, Nawrocki ST, et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014; 10:1403–14; PMID:24991835; http://dx.doi.org/10.4161/auto.29231
   PubMed Web of Science ®Google Scholar
• Sehgal AR, Konig H, Johnson DE, Tang D, Amaravadi RK, Boyiadzis M, Lotze MT. You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia. 2015 Mar; 29(3):517-525; http://dx.doi.org/10.1038/leu.2014.349
   Google Scholar
• Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012; 149:307–21; PMID:22500798; http://dx.doi.org/10.1016/j.cell.2012.02.053
   PubMed Web of Science ®Google Scholar
• Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 1998; 12:502–13; PMID:9472019; http://dx.doi.org/10.1101/gad.12.4.502
   PubMed Web of Science ®Google Scholar
• Diab S, Teo T, Kumarasiri M, Li P, Yu M, Lam F, Basnet SK, Sykes MJ, Albrecht H, Milne R, et al. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation. ChemMedChem 2014; 9:962–72; PMID:24677692; http://dx.doi.org/10.1002/cmdc.201300552
   PubMed Web of Science ®Google Scholar
• Lim S, Saw TY, Zhang M, Janes MR, Nacro K, Hill J, Lim AQ, Chang CT, Fruman DA, Rizzieri DA, et al. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci U S A 2013; 110:E2298–307; PMID:23737503; http://dx.doi.org/10.1073/pnas.1301838110
   PubMed Web of Science ®Google Scholar
• Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69:4286–93; PMID:19401449; http://dx.doi.org/10.1158/0008-5472.CAN-08-4765
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30–9; PMID:25399551; http://dx.doi.org/10.1056/NEJMoa1412690
   PubMed Web of Science ®Google Scholar